# Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults

> **NCT00442169** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 208 (actual)

## Conditions studied

- West Nile Fever

## Interventions

- **BIOLOGICAL:** ChimeriVax-WN02 Low Dose
- **BIOLOGICAL:** ChimeriVax-WN02 Medium Dose
- **BIOLOGICAL:** ChimeriVax-WN02 High Dose
- **BIOLOGICAL:** 0.9% Saline solution
- **BIOLOGICAL:** ChimeriVax-WN02 High Dose
- **BIOLOGICAL:** 0.9 % NaCl solution

## Key facts

- **NCT ID:** NCT00442169
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2008-06
- **Final completion:** 2009-04
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2016-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00442169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00442169, "Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00442169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*